Posted by Michael Wonder on 25 Jan 2021
FDA grants toripalimab fast track designation for mucosal melanoma
25 January 2021 - Junshi Biosciences announced today that U.S. FDA has granted toripalimab fast track designation for the first-line treatment of mucosal melanoma.
Meanwhile, the FDA has also approved the Investigational ew drug application for a global Phase 3 trial of toripalimab in combination with axitinib versus pembrolizumab for the first-line treatment of patients with advanced mucosal melanoma.
